Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Invivyd, Inc. (IVVD : NSDQ)

• Company Description    INVIVYD INC. is a biopharmaceutical company. It involved in developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. INVIVYD INC., formerly known as Adagio Therapeutics, is based in WALTHAM, Mass. Number of Employees: 100

• Price / Volume Information    Yesterday's Closing Price: $2.47 Daily Weekly Monthly 20 Day Moving Average: 4,503,413 shares Shares Outstanding: 233.12 (millions) Market Capitalization: $575.81 (millions) Beta: 0.61 52 Week High: $3.07 52 Week Low: $0.35 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 11.26% 11.45% 12 Week 30.69% 28.58% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1601 TRAPELO ROAD SUITE 178 - WALTHAM,MA 02451 USA ph: 781-819-0080 fax: - investors@invivyd.com https://invivyd.com

• General Corporate Information    Officers Marc Elia - Chairman of the Board of Directors William Duke - Chief Financial Officer Tamsin Berry - Director Srishti Gupta - Director Christine Lindenboom - Director Peer Information Invivyd, Inc. (CORR.) Invivyd, Inc. (RSPI) Invivyd, Inc. (CGXP) Invivyd, Inc. (BGEN) Invivyd, Inc. (GTBP) Invivyd, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00534A102 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/19/26 Share - Related Items Shares Outstanding: 233.12 Most Recent Split Date: (:1) Beta: 0.61 Market Capitalization: $575.81 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.08 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.56 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/19/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 6.19 Price/Cash Flow: - Price / Sales: 11.51 EPS Growth vs. Year Ago Period: 88.24% vs. Previous Quarter: 50.00% Sales Growth vs. Year Ago Period: 41.17% vs. Previous Quarter: 11.39% ROE 12/31/25 - - 09/30/25 - -92.97 06/30/25 - -177.89 ROA 12/31/25 - - 09/30/25 - -51.88 06/30/25 - -90.96 Current Ratio 12/31/25 - - 09/30/25 - 2.47 06/30/25 - 1.33 Quick Ratio 12/31/25 - - 09/30/25 - 2.47 06/30/25 - 1.33 Operating Margin 12/31/25 - - 09/30/25 - -119.63 06/30/25 - -238.33 Net Margin 12/31/25 - - 09/30/25 - -119.63 06/30/25 - -238.33 Pre-Tax Margin 12/31/25 - - 09/30/25 - -119.63 06/30/25 - -238.33 Book Value 12/31/25 - - 09/30/25 - 0.40 06/30/25 - 0.36 Inventory Turnover 12/31/25 - - 09/30/25 - 0.51 06/30/25 - 0.23 Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©